Strive Financial Group
ACRS icon

Strive Financial Group’s Aclaris Therapeutics ACRS Stock Holding History

Strive Financial Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.2K Buy
+2,500
New +$14.3K ﹤0.01% 632

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Decheng Capital
Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Strive Financial Group's ACRS Position: Q3 2026 in Review

Strive Financial Group opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 2,500 shares worth $13.2K. The stake represents ﹤0.01% of the portfolio and ranks #632 among its holdings.

111 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Strive Financial Group held 2,500 shares of Aclaris Therapeutics worth $13.2K as of Q3 2026.
  • Aclaris Therapeutics was a new Strive Financial Group position in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #632 holding.
  • 111 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.